They agreed to charge the U.S. government no more for new drugs than the prices paid by other well-off countries. The agreements will allow state Medicaid programs to access lower prices from the nine ...
Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – ...
The Dow Jones tracks 30 of the largest American companies across different sectors. Verizon, Chevron, and Merck hold the ...
UMBRELLA IN MY FULL FORECAST. THANK YOU MARY ELLEN. TODAY, HUNDREDS OF NONPROFITS AND ORGANIZATIONS THAT SERVE THE SUSQUEHANNA VALLEY ARE ASKING FOR YOUR DONATIONS AS PART OF THE LARGEST SINGLE DAY ...
(RTTNews) - Amgen (AMGN) announced detailed findings from its Phase 3 VESALIUS-CV clinical trial, revealing that Repatha (evolocumab) significantly reduces major adverse cardiovascular events (MACE) ...
Nov 8 (Reuters) - Adding Amgen's (AMGN.O), opens new tab cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have never had a heart attack ...
The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients. 3,4 Repatha is approved in 74 countries, including the U.S., Japan, Canada ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from its cardiovascular portfolio, including late-breaking results from the Phase 3 VESALIUS-CV ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke New data from the VESALIUS-REAL global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback